34 results about "FGF1" patented technology

There is provided an FGF2 substitute containing medicinal composition which comprises, as an active ingredient, a chimeric protein comprising the amino acid sequence of an FGF1 protein in which a partial sequence including a sequence of at least positions 62-83 within a sequence of positions 41-83 is substituted with a partial sequence at the corresponding positions in the amino acid sequence of an FGF2 protein; and the remaining region is formed of the amino acid sequence of FGF1. In particular, this medicinal composition is used for wound healing and for the prevention and treatment of radiation-induced damage, and it exhibits a pharmacological action superior to that of an FGF2 medicinal composition, and further, it can be easily formulated into a preparation.

Stem cells are mobilized into the peripheral blood by a method comprising the steps of: (i) administering to an individual at least one of the following: FGF1 and FGF2, and also at least one of the following: VEGF, VEGFA, VEGFB, PLGF, VEGF121, VEGF145, VEGF165, VEGF189, and VEGF206; (ii) isolating the peripheral blood stem cells (PBSC) by apheresis; and (iii) treating a patient suffering from organ disease with PBSC. Alternatively, gene therapy is used for the induction of the stem cells into the peripheral blood, wherein the gene therapy formulation comprises AD5FGF-4 or VEGF165 plasmid DNA. Additionally, the progress of the treatment of the organ disease is monitored by using an ultrasound unit.

The invention relates to a preparation method of FGF1 sericin protein gel with activity for promoting cell proliferation and a product thereof. The preparation method comprises the following steps that sericin protein containing human FGF1 protein is extracted by human FGF1 gene modifying silk, and a sericin protein solution containing human FGF1 protein is obtained; after renaturation, an FGF1 sericin protein aqueous solution is obtained after dialysis with water, and FGF1 sericin protein hydrogel is obtained by centrifugation; and the FGF1 sericin protein hydrogel is placed at 4 DEG C, an FGF1 sericin protein gel material is formed by cross-linking of a chemical cross-linking agent or inducement of an inducer. The prepared gel material has the activity of promoting cell proliferation andhas broad application potential in tissue engineering.

The present invention provides a method for predicting the treatment response of a human gastroesophageal cancer patient, the method comprising: a) measuring the gene expression of at least 3 of the following genes: CDH1, CDK6, COX2, ELOVL5, GATA4, EGFR, TBCEL, FGF7, CDH17, FNBP1, PIP5K1B, TWIST, CD44, MET, CEACAM1, TOX3, GLIPR2, GSTP1, RON, TMEM136, MYB, BRCA2, FGF1, POU5F1, EPR, DPYD, ABL2 and SH3RF1 in a sample obtained from the gastroesophageal tumour of the patient to obtain a sample gene expression profile of at least said genes; and b) making a prediction of the treatment response and / or prognosis of the patient based on the sample gene expression profile. Also provided are related computer-implemented methods and methods of treatment of gastroesophageal cancer.

The invention relates to a skin anti-ageing composition, in particular to a skin care product containing kinds of biological factors, and belongs to the fields of cosmetics and biotechnologies. Every10 ml of composition is composed of, by content, 5-40 mg of transparent hyaluronic acid, 50-400 mg of hydrolyzed collagen, 1-5 ml of mesenchymal stem cell secretion, 1-5 ng of EGF, 1-8 ng of b-FGF1 and 10 ml of sufficiently-supplemented purified water. The skin anti-ageing composition has the advantages that a formula is safe and effective, there are no allergic substances and preservative, ageingresistance and wrinkle removal are effective, the premature ageing of the skin is improved greatly, meanwhile, it is avoided that nutrition excess makes the skin burdened, and new skin problems appear, and the skin anti-ageing composition is particularly suitable for allergic skin.

The invention discloses a solubleand efficient recombinant expression methodfor fibroblast growth factor protein. In the method, as for an escherichia coli strain of a carrier containing coding-recombinant fibroblast growth factor family protein, expression of intracellularactive protein is promoted by adding a certain dosage of monosaccharide during induction.The fibroblast growth factor family protein comprises FGF1, FGF2, FGF4, FGF7, FGF8, FGF9, FGF11, FGF15, FGF18, FGF21, FGF23 and mutants of the fibroblast growth factor family protein. As for the process that the certain dosage of monosaccharide is added during induction, the monosaccharide is supplemented into before an inductive agent is added, or the monosaccharide is supplemented into while an inductive agent is added, or the monosaccharide is supplemented into after the inductive agent is added. The technology prejudice that expression of lac and araoperons is inhibited by glucose in escherichia colirecombinant is overcome inthe technical field, and the method capable of efficiently promoting expression of the fibroblast growth factor protein in escherichia coli is applied.

The invention discloses a mutated fibroblast growth factor (FGF) 1 and methods of use. The present disclosure provides FGF1 mutant proteins, such as those having an N-terminal deletion, point mutation(s), or combinations thereof, which can reduce blood glucose in a mammal. Such mutant FGF1 proteins can be part of a chimeric protein that includes a [Beta]-Klotho-binding protein, an FGFRlc-binding protein, a [Beta]-Klotho-binding protein and a FGFRlc-binding protein, a C-terminal region from FGF 19 or FGF21. In some examples, mutant FGF1 proteins have reduced mitogenic activity. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed molecules to reduce blood glucose levels are also provided.

The invention relates to a preparation method and a product of a sericin-agarose composite gel having the activity of promoting cell proliferation and a product, sericin of recombinant FGF1 protein and FGF2 protein can be extracted from transgenic human FGF1 gene and human FGF2 gene silk, a sericin solution containing the recombinant FGF1 protein and the FGF2 protein is obtained, the sericin solution containing the recombinant FGF1 protein and the FGF2 protein is renatured to obtain a renatured sericin solution containing the recombinant FGF1 protein and the FGF2 protein, the renatured sericinsolution and an agarose solution are mixed for injection molding and molding to obtain the sericin-agarose composite gel having the activity of promoting cell proliferation, and the prepared composite gel has good stability, can better support the proliferation and growth of NIH3T3 cells, and has low cytotoxicity, and has broad application prospects in tissue engineering.

The invention relates to recombinant human acidic fibroblast growth factor (FGF1), in particular relates to a preparation method of FGF1 full-length protein by utilizing escherichia coli, which comprises the following steps of amplifying by utilizing a PCR (polymerase chain reaction) method to obtain a human FGF1 full-length gene PCR product; and digesting the PCR product by using incision enzyme. According to the preparation method, the full-length gene of the human acidic fibroblast growth factor is cloned to a pMAL-p5X expression carrier; the recombinant plasmid expresses the FGF1 full-length protein containing MBP (myelin basic protein) fusion label at high efficiency in the escherichia coli, wherein the protein in soluble expression; and the protein with MBP infusion label is purified by utilizing an MBP affinity column, and a complete FGF1 protein without the fusion label is prepared by utilizing TEV (tobacco etch virus) enzyme binding site and using TEV digested and purified infusion protein. The FGF1 full-length protein has high solubility and higher purity.

The invention provides a FGF1-FGF21 chimeric protein. The FGF1-FGF21 chimeric protein comprises a FGF1 mutant and a C-tail of FGF21. The FGF1-FGF21 chimeric protein reduces the side effects of mitogenesis and proliferation, and has long-acting blood-sugar-reducing and lipid-lowering activities and other activities.

Stem cells are mobilized into the peripheral blood by a method comprising the steps of: (i) administering to an individual at least one of the following: FGF1 and FGF2, and also at least one of the following: VEGF, VEGFA and VEGF165; (ii) isolating the peripheral blood stem cells (PBSC) by apheresis; and (iii) injecting the PBSC into a patient suffering from chronic heart disease. Alternatively, gene therapy is used for the induction of the stem cells into the peripheral blood, wherein the gene therapy formulation comprises AD5FGF-4 or VEGF165 plasmid DNA. Additionally, the progress of the treatment of the chronic heart disease is monitored by using an echocardiogram unit.

The invention relates to the technical field of blood vessel production inhibition and discloses application of MiR-205-5p in preparation of a vascularization agent. The application comprises the following operations: detecting expression of miR-205-5p and CD31 in human gastric carcinoma tissue and liver metastatic tumor by adopting quantitative real-time qRT-PCR; detecting formation of capillaryvessels of endothelial cells of human umbilical veins in vitro, and researching actions of silence and high expression of the miR-205-5p in a body dorsa body wrinkle chamber model; and detecting influence on expression of VEGFA and FGF1 caused by the miR-205-5p by adopting the qRT-PCR and Western blots, wherein the MiR-205-5p lowers the expression of the VEGFA and FGF1 through an ERK signal way and direct targeting. According to the application, the expression of the VEGFA and FGF1 is lowered through the ERK signal way and direct targeting, so that vasculogenesis of gastric carcinoma is inhibited; particularly, the MiR-205-5p exerts an important action in the vasculogenesis; and the miR-205-5p can be used for lowering the formation of newborn blood vessels through negatively regulating andcontrolling the expression of the VEGFA, so that the miR-205-5p is a carcinoma inhibiting factor through inhibiting the vasculogenesis in the gastric carcinoma, and also exerts an important action onproliferation and invasion of different types of tumors.

The invention discloses a preparation method of a gene recombinant cell based on MSC (mesenchymal stem cells), which comprises the steps of: S101: respectively cloning coding genes of IL-35, IL-22 and FGF1 into an eukaryotic expression vector pDisplay with a transmembrane region structure to form cell membrane surface display plasmids (pDIL35, pDIL22 and pDFGF1) of the IL-35, the IL-22 and the FGF1; S102: preparing an hUC-MSC cell; and S103: equivalently mixingthe pDIL35 plasmid, the pDIL22 plasmid and the pDFGF1 plasmid and transfected into the MSC so as to generate an MSCd12235 cell. According to the invention, a plurality of cell factors with the known biological activity are expressed on the surface of one functional cell to form the gene recombinant cell with a novel biological function. The functional cell provides an immobilized action surface for the active factor, and the active factor endows the original cell with a new function and the functional cell is applied to treatment of diabetes mellitus.

The present invention relates to application of a microRNA-326 inhibitor to the preparation of medicaments for treating cataract. By experiments, the present invention proves that microRNA-326 can inhibit the expression of FGF1 to further achieve down-regulation of expression of betaB2 crystal protein; and the content change if betaB2 crystal protein is a key factor in cataract, and the down-regulation of expression of betaB2 crystal protein causes cataract. The invention suggests that inhibition of microRNA-326 can be used for the treatment of cataract, and microRNA-326 can be used as marker for cataract diagnosis.

The invention provides a breast cancer diagnosis kit based on combined detection of fibroblast growth factors FGF1 and FGF10 and interleukin IL6, and belongs to the field of protein detection. The breast cancer diagnosis kit comprises reagents for quantitatively detecting the FGF1, the FGF10 and the interleukin IL6. The invention also provides a preparation method of the kit. The kit for clinically diagnosing breast cancer has the advantages of convenience in operation, low cost, good specificity and good accuracy.

The invention discloses a baical skullcap root extract-FGF1 compound. The baical skullcap root extract-FGF1 compound is a compound obtained by co-incubating a baical skullcap root extract and FGF1, wherein the baical skullcap root extract is baicalin, oroxylin A-7-O-beta-D-glucuronide or wogonoside, and the obtained compound is an FGF1-baicalin compound, an FGF1-oroxylin A-7-O-beta-D-glucuronide compound or an FGF1-wogonoside compound. The incubating comprises the following steps: 1) dissolving the baical skullcap root extract with methanol, performing blow-drying with nitrogen, and performingre-dissolving with water; and dissolving FGF1 target protein in a PBS buffer solution, performing mixing with the baical skullcap root extract aqueous solution, performing incubating at 36-38 DEG C for 25-35 min, and performing vacuum freeze-drying. The invention further discloses an application of the FGF1-baicalin compound, the FGF1-oroxylin A-7-O-beta-D-glucuronide compound or the FGF1-wogonoside compound in the aspect of promoting cell proliferation.

The invention provides an FGF1 (Fibroblast Growth Factor 1) mutant. The amino acid sequence of the mutant has mutation of Lys127, Lys128 and / or Lys133 on the basis of SEQ ID NO:1, and the mutant has a function of reducing cell division promotion and proliferation of a FGF1, but still has the activity of reducing blood sugar and the like.

The invention discloses an application of a cytochrome C oxidase subunit 4 subtype 2 (COX4I2) in preparation of a predictive biomarker for prognosis and immunotherapy reactivity of a human colorectal cancer patient. The correlation between the COX4I2 level and clinical characteristics and biological effects thereof is evaluated in vitro and in vivo, it is found that rising of the COX4I2 level is related to poor prognosis of a patient suffering from the colorectal cancer, experimental research further observes that COX4I2 can participate in epithelial-mesenchymal transition (EMT) of colorectal cancer cells, expression of fibroblast growth factor 1 (FGF1) is promoted, and the COX4I2 can be used for treating the poor prognosis of the patient suffering from the colorectal cancer. Tumor-related fibroblasts are activated and recruited; and tumor angiogenesis is promoted. Therefore, the COX4I2 can be used as a prognosis biomarker of a colorectal cancer patient, and can also be a new target for treatment development.

The invention discloses a recombinant expression vector of FGFR3 mutant. The recombinant expression vector contains mutant FGFR3 delta7-9 of deletion exons 7, 8 and 9. The nucleotide sequence of the deletion part of the mutant FGFR3 delta7-9 is shown as SEQ ID NO.1. In addition, the invention further discloses a construction method of the recombinant expression vector of the FGFR3 mutant. The construction method comprises the following steps: (1) amplifying DNA fragments of the FGFR3 mutant through an SOE PCR (gene splicing by overlap extension PCR) method; (2) carrying out gel electrophoresis on the amplification product, and carrying out rubber cutting and recycling on target genes; (3) carrying out double enzyme digestion on the PCR product; and (4) connecting the target fragments and a carrier fragment. In addition, the invention further discloses an application of the recombinant expression vector of FGFR3 mutant. The experiment shows that the recombinant expression vector has good application values in identifying the affinity of FGF1 / FGF2 and FGFR3 as well as the mutant thereof, and the capacity of forming a dimer of FGFR3 and the mutant thereof, as well as in identifying activation of tyrosine kinase areas of FLAG-FGFR3 IIIc, FLAG-FGFR3 delta 7-9, and FLAG-FGFR3 AT-I.

The invention provides a biomarker combination for diagnosing non-obstructive azoospermia. The biomarker combination comprises FGF1 (fibroblast growth factor 1), FGF9 (fibroblast growth factor 9) and FGF14 (fibroblast growth factor 14), the biomarker combination can be used for preparing an ELISA (enzyme-linked immunosorbent assay) detection kit, the non-obstructive azoospermia is diagnosed by detecting expression conditions of FGF1, FGF9 and FGF14 in a blood sample of a patient, the pain of the patient can be greatly relieved, and the application prospect is wide.

The invention aims to provide a preparation method and application of a CHIR99021 and FGF1 nanoparticle combined myocardial tissue block. The preparation method of the CHIR99021 and FGF1 nanoparticlecombined myocardial tissue block comprises the following steps of: 1) preparing CHIR99021 and FGF1 nanoparticles; and 2) preparing a human induced pluripotent stem cell-derived myocardial tissue block(iCM-C + F-NP Patch) containing the CHIR99021 and FGF1 nanoparticles. The prepared human induced pluripotent stem cell-derived myocardial tissue block (iCM-C + F-NP Patch) containing the CHIR99021 and FGF1 nanoparticles is applied to treatment of animal ischemic heart disease. The CHIR99021 and FGF1 are combined for use, so that proliferation of hiPSC-CMs can be promoted and apoptosis can be reduced through synergistic effect; when the CHIR99021 and FGF1 are used for treating the animal ischemic heart disease, more hiPSC-CMs can be survived after transplantation, myocardial infarction can beeffectively relieved, periodical activity of myocardial infarction transplantation cells can be promoted, angiogenesis can be promoted, apoptosis reaction can be reduced, and the CHIR99021 and FGF1 nanoparticle combined myocardial tissue block can be applied to clinical treatment of the myocardial infarction.